Detail akcie Cypherpunk Technologies Inc online

Business Summary: Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cypherpunk Technologies Inc revenues was not reported. Net loss applicable to common stockholders decreased 32% to $35.4M. Lower net loss reflects Research and development - Balancing va decrease of 44% to $23.7M (expense), General and Administrative - Balancing decrease of 32% to $5.4M (expense), Stock-based Compensation in R&D decrease of 50% to $1M (expense).